Fate Therapeutics Inc (NASDAQ:FATE)
| 55.76 BATS BZX Real-Time Price As of 11:47am ET |  +0.87 / +1.58%Today’s Change | 42.64 Today|||52-Week Range 121.16 | -38.68% Year-to-Date |
Latest FATE News | Press Releases
| Fate Therapeutics Inc (FATE) President and CEO J Scott Wolchko Sold $3.6 million of Shares Oct 26 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 54.89 |
| Today’s open | 55.11 |
| Day’s range | 54.33 - 56.46 |
| Volume | 32,380 |
| Average volume (3 months) | 991,856 |
| Market cap | $5.6B |
Data as of 11:47am ET, 10/28/2021
Growth & Valuation
| Earnings growth (last year) | -46.22% |
| Earnings growth (this year) | -5.91% |
| Earnings growth (next 5 years) | -12.87% |
| Revenue growth (last year) | +194.33% |
| P/E ratio | NM |
| Price/Sales | 238.32 |
| Price/Book | 13.47 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HALOHalozyme Therapeutic... | +1.11 | +2.97% |
| TWSTTwist Bioscience Cor... | +5.80 | +5.07% |
| TLRYTilray Inc | +0.13 | +1.26% |
| ---- |
Data as of 11:46am ET, 10/28/2021
Financials
| Next reporting date | November 4, 2021 |
| EPS forecast (this quarter) | -$0.57 |
| Annual revenue (last year) | $31.4M |
| Annual profit (last year) | -$173.4M |
| Net profit margin | -551.59% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
